10-KPeriod: FY2005

JOHNSON & JOHNSON Annual Report, Year Ended Jan 2, 2005

Filed March 15, 2005For Securities:JNJ

Summary

Johnson & Johnson's 2004 10-K filing presents a diversified global healthcare company with strong performance across its three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The company emphasizes its commitment to innovation and research, supported by a robust patent and trademark portfolio. J&J operates with a significant global presence, indicating resilience and broad market reach. Investors can note the company's status as an accelerated filer, suggesting robust financial reporting practices. While the filing does not explicitly detail financial performance figures in the provided excerpt, it outlines the company's structure, business segments, and commitment to regulatory compliance, all of which are crucial indicators for evaluating its stability and future growth potential. The incorporation of the Annual Report to Shareholders and Proxy Statement suggests that detailed financial and operational data are available in those documents.

Key Highlights

  • 1Diversified business model across Consumer, Pharmaceutical, and Medical Devices & Diagnostics segments.
  • 2Global operational presence providing market breadth and resilience.
  • 3Emphasis on research and development (R&D) as a core strategy for growth.
  • 4Strong intellectual property portfolio including patents and trademarks.
  • 5Operates as an accelerated filer, indicating adherence to timely and rigorous financial reporting standards.
  • 6Company is subject to significant regulatory oversight across its business segments.
  • 7The filing references incorporated documents (Annual Report, Proxy Statement) which contain more detailed financial information.

Frequently Asked Questions

Johnson & Johnson operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Each segment contributes to the company's overall diversified healthcare business.

Yes, the filing indicates that Johnson & Johnson has a global presence, operating in various geographic areas. This global reach is a key aspect of its business strategy.

Patents and trademarks are crucial for Johnson & Johnson as they protect the company's innovations and products, particularly in the Pharmaceutical and Medical Devices segments, providing a competitive advantage and supporting future revenue streams.

Being an accelerated filer means that Johnson & Johnson is required to file its periodic reports with the SEC more frequently and with a shorter turnaround time compared to non-accelerated filers. This generally indicates a larger market capitalization and a more established reporting structure.